RxDoctor Payments Data

Changjian Chen, MD

Gastroenterology · Kokomo, INNPI 1649223272

Payments from drug & device makers

$1,292in general payments, 2019–2025

Across 73 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$329
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$174
  • Takeda Pharmaceuticals U.S.A., Inc.$115
  • Pfizer$82
  • Johnson & Johnson$82
  • Regeneron Healthcare Solutions, Inc.$60
  • plus $450 from 16 others

What the payments were for

  • Food & beverage$1,27999%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,292 in reported general payments places this provider in the 35th percentile of 323 gastroenterology providers in Indiana.

See all gastroenterology providers in Indiana

Medicare billing

Part B allowed, 2024
$146,722
Medicare patients
647
Services billed
1,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab19$489,290
EpclusaSofosbuvir/Velpatasvir19$455,115
LinzessLinaclotide266$254,247
Humira(Cf) PenAdalimumab26$211,732
XifaxanRifaximin58$170,131
CreonLipase/Protease/Amylase23$42,288
Mesalamine40$34,311
Budesonide ErBudesonide27$30,502
MotegrityPrucalopride Succinate34$27,204
Mesalamine ErMesalamine83$25,584
Alosetron Hcl13$21,743
Lubiprostone133$20,084
Colestipol Hcl240$13,849
MovantikNaloxegol Oxalate16$9,538
Dexlansoprazole DrDexlansoprazole46$9,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$82$489,29019 claims
GileadEpclusa$34$455,11519 claims
AbbVieLinzess, Creon$329$296,534289 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$174$170,13158 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$115$27,20434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 323 gastroenterology providers in Indiana.

Other gastroenterology in Kokomo

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →